摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-bromo-4,5-dichloro-1-({[2-(trimethylsilyl)ethyl]oxy}methyl)-1H-imidazole | 1007832-80-5

中文名称
——
中文别名
——
英文名称
2-bromo-4,5-dichloro-1-({[2-(trimethylsilyl)ethyl]oxy}methyl)-1H-imidazole
英文别名
2-bromo-4,5-dichloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole;N-(2-bromo-4,5-dichloro-1-{[2-(trimethylsilyl)ethoxy]methyl})-1H-imidazole;2-[(2-bromo-4,5-dichloroimidazol-1-yl)methoxy]ethyl-trimethylsilane
2-bromo-4,5-dichloro-1-({[2-(trimethylsilyl)ethyl]oxy}methyl)-1H-imidazole化学式
CAS
1007832-80-5
化学式
C9H15BrCl2N2OSi
mdl
——
分子量
346.126
InChiKey
KXAVNTDOVCIUJX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    374.7±52.0 °C(Predicted)
  • 密度:
    1.44±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.26
  • 重原子数:
    16
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    27
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    2-bromo-4,5-dichloro-1-({[2-(trimethylsilyl)ethyl]oxy}methyl)-1H-imidazole正丁基锂三甲基氯硅烷 作用下, 以 四氢呋喃正己烷 为溶剂, 反应 1.58h, 生成 2-[(4,5-dichloroimidazol-1-yl)methoxy]ethyl-trimethylsilane
    参考文献:
    名称:
    Rational Design of Potent Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
    摘要:
    A new series of non-nucleoside reverse transcriptase inhibitors based on an imidazole-amide biarylether scaffold has been identified and shown to possess potent antiviral activity against HIV-1, including the NNRTI-resistant Y188L mutated virus. X-ray crystallography of inhibitors bound to reverse transcriptase, including a structure of the Y188L RT protein, was used extensively to help identify and optimize the key hydrogen-bonding motif. This led directly to the design of compound 43 that exhibits remarkable antiviral activity (EC50 < 1 nM) against a wide range of NNRTI-resistant viruses and a favorable pharmacokinetic profile across multiple species.
    DOI:
    10.1021/jm301294g
  • 作为产物:
    参考文献:
    名称:
    Vanilloid receptor ligands and their use in treatments
    摘要:
    治疗苯并咪唑类药物及其组合物,用于治疗急性、炎症性和神经病性疼痛、牙痛、普通头痛、偏头痛、集群头痛、混合血管和非血管综合症、紧张性头痛、一般炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠病、炎症性眼疾、炎症性或不稳定膀胱疾病、银屑病、具有炎症成分的皮肤疾病、慢性炎症状况、炎症性疼痛和相关的过敏症和痛觉过敏、神经病性疼痛和相关的过敏症和痛觉过敏、糖尿病神经病疼痛、烧伤后神经病疼痛、交感神经维持性疼痛、感觉神经缺失综合症、哮喘、上皮组织损伤或功能障碍、单纯疱疹、呼吸、泌尿、胃肠或血管区域内脏动力障碍、伤口、烧伤、过敏性皮肤反应、瘙痒、白癜风、一般胃肠疾病、胃溃疡、十二指肠溃疡、腹泻、由坏死剂引起的胃损伤、毛发生长、血管运动或过敏性鼻炎、支气管疾病或膀胱疾病。
    公开号:
    US20060084640A1
点击查看最新优质反应信息

文献信息

  • [EN] INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION<br/>[FR] INHIBITEURS D'HISTONE DÉSACÉTYLASE UTILES POUR LE TRAITEMENT OU LA PRÉVENTION D'UNE INFECTION PAR LE VIH
    申请人:MERCK SHARP & DOHME
    公开号:WO2020028150A1
    公开(公告)日:2020-02-06
    The present invention relates to Compounds of Formula (I): Formula (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, Ra, Rb, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treating or preventing HIV infection in a subject.
    本发明涉及公式(I)的化合物:公式(I)及其药学上可接受的盐或前药,其中R1、R2、R3、Ra、Rb、A和B如本文所定义。本发明还涉及包含至少一种公式(I)化合物的组合物,以及使用公式(I)化合物治疗或预防受试者的HIV感染的方法。
  • CHEMICAL COMPOUNDS
    申请人:Chong PEK Yoke
    公开号:US20100216746A1
    公开(公告)日:2010-08-26
    The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.
    本发明涉及一种非核苷类逆转录酶抑制剂,以及制备和使用该类化合物的方法。具体而言,本发明包括使用这些化合物治疗人类免疫缺陷病毒感染的方法。
  • Chemical compounds
    申请人:GlaxoSmithKline LLC
    公开号:US08304419B2
    公开(公告)日:2012-11-06
    The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.
    本发明涉及一种非核苷类逆转录酶抑制剂化合物,以及制备和使用该化合物的方法。具体而言,本发明涉及使用这些化合物治疗人类免疫缺陷病毒感染的方法。
  • IMIDAZOLOPYRIMIDINES AND IMIDAZOLOTRIAZINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP)
    申请人:Jones Philip
    公开号:US20100173895A1
    公开(公告)日:2010-07-08
    The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo-or radiosensitizers for cancer treatment.
    本发明涉及式(I)化合物及其药学上可接受的盐或互变异构体,其为聚(ADP-核糖)聚合酶(PARP)的抑制剂,因此可用于治疗癌症、炎症性疾病、再灌注损伤、缺血性状况、中风、肾功能衰竭、心血管疾病、除心血管疾病以外的血管疾病、糖尿病、神经退行性疾病、逆转录病毒感染、视网膜损伤、皮肤衰老和紫外线诱导的皮肤损伤,并可作为化疗或放疗增敏剂用于癌症治疗。
  • WO2008/154271
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多